Nubis (NBIS) Surges 11% on Goldman Sachs Buy Rating

Nubis Inc. (NBIS) jumped 11.31% to $49.31 on Monday after Goldman Sachs initiated coverage with a Buy rating, citing strong growth prospects.

• Year-to-date performance: NBIS is now up 61.46% in 2025.
• Today’s move: +$5.01 on the day, closing at $49.31.

What does Nubis do?
Nubis is a health-tech company specializing in cloud-based neurodiagnostic testing and analysis. Its proprietary platform enables remote EEG testing, helping neurologists diagnose conditions such as epilepsy and sleep disorders with greater speed and accessibility. The company aims to disrupt traditional hospital-based neurodiagnostic workflows through scalable digital tools.

Goldman’s coverage signals institutional confidence in Nubis’ ability to expand its tech-enabled healthcare platform, especially as demand rises for decentralized and remote diagnostics.